Jyotsna Kapoor

New Delhi, DL, India

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Is it Necessary to Achieve a Very Good Partial Response Prior to Transplant? Comparison of Outcomes in Pre-Transplant Partial Response Versus Very Good Partial Response or Deeper.

Is it Necessary to Achieve a Very Good Partial Response Prior to Transplant? Comparison of Outcomes in Pre-Transplant Partial Response Versus Very Good Partial Response or Deeper.

Journal: Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion

Published: April 15, 2025

Second stem cell transplantation for treatment of relapsed/refractory multiple myeloma after first autologous stem cell transplant: A 15-year retrospective institutional analysis.

Second stem cell transplantation for treatment of relapsed/refractory multiple myeloma after first autologous stem cell transplant: A 15-year retrospective institutional analysis.

Journal: Indian journal of cancer

Published: October 03, 2023

HIV Associated Lymphomas: A Double-Edged Sword.

HIV Associated Lymphomas: A Double-Edged Sword.

Journal: Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion

Published: November 01, 2022

Attenuated Dose Dasatinib in Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase Patients in India.

Attenuated Dose Dasatinib in Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase Patients in India.

Journal: Clinical lymphoma, myeloma & leukemia

Published: September 21, 2022

Busulfan and cyclophosphamide-based conditioning regimen still holds the promise of being a safe and efficacious regimen for allogeneic transplantation in patients with transfusion-dependent thalassemia, even in high risk.

Busulfan and cyclophosphamide-based conditioning regimen still holds the promise of being a safe and efficacious regimen for allogeneic transplantation in patients with transfusion-dependent thalassemia, even in high risk.

Journal: European journal of haematology

Published: May 21, 2022

A Retrospective Cohort Study of Upfront Nilotinib in Chronic Myeloid Leukemia: A Single-Center Experience.

A Retrospective Cohort Study of Upfront Nilotinib in Chronic Myeloid Leukemia: A Single-Center Experience.

Journal: South Asian journal of cancer

Published: January 05, 2022

Daratumumab-based therapy after prior Azacytidine-Venetoclax in an octagenerian female with BPDCN (blastic plasmacytoid dendritic cell neoplasm) - a new perspective.

Daratumumab-based therapy after prior Azacytidine-Venetoclax in an octagenerian female with BPDCN (blastic plasmacytoid dendritic cell neoplasm) - a new perspective.

Journal: Leukemia & lymphoma

Published: June 21, 2021

High Risk Acute Promyelocytic Leukemia - An Enigma for Hematologists: Optimizing Treatment with APML-4 Protocol.

High Risk Acute Promyelocytic Leukemia - An Enigma for Hematologists: Optimizing Treatment with APML-4 Protocol.

Journal: Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion

Published: February 11, 2021

An "impossible" harvest-GCSF-induced immune thrombocytopenia in an autologous stem cell transplant recipient with multiple myeloma.

An "impossible" harvest-GCSF-induced immune thrombocytopenia in an autologous stem cell transplant recipient with multiple myeloma.

Journal: Bone marrow transplantation

Published: January 20, 2021

Retrospective Study of Carfilzomib-Pomalidomide-Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients in a Tertiary Care Hospital in India.

Retrospective Study of Carfilzomib-Pomalidomide-Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients in a Tertiary Care Hospital in India.

Journal: Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion

Published: January 14, 2021

Study of clinical characteristics, risk factors and outcomes for tuberculosis post allogeneic stem cell transplant: never count it out.

Study of clinical characteristics, risk factors and outcomes for tuberculosis post allogeneic stem cell transplant: never count it out.

Journal: Therapeutic advances in infectious disease

Published: December 05, 2020

Experience with combination of hydroxyurea and low-dose thalidomide in transfusion-dependent beta thalassemia patients.

Experience with combination of hydroxyurea and low-dose thalidomide in transfusion-dependent beta thalassemia patients.

Journal: Annals of hematology

Published: October 02, 2020

Showing 1-12 of 23

Last Updated: 09/26/2026